Stereotactic Ablative Body Radiotherapy for Lung Metastases: Where is the Evidence and What are We Doing With It?

Shankar Siva; Ben J Slotman

doi:https://doi.org/10.1016/j.semradonc.2017.03.003

Stereotactic Ablative Body Radiotherapy for Lung Metastases: Where is the Evidence and What are We Doing With It?

Shankar Siva, Ben J Slotman

Research output: Contribution to journal › Review article › Academic › peer-review

27 Citations (Scopus)

Abstract

This review provides an overview of the use of stereotactic ablative body radiotherapy (SABR) for pulmonary metastases. The local control rates after SABR are generally >90%. Whether this also translates into a significant improvement in overall survival is the subject of ongoing studies. New exciting opportunities including the integration of SABR with targeted and immune therapies as well as some competing treatment strategies are discussed.

Original language	English
Pages (from-to)	229-239
Number of pages	11
Journal	Semininars in Radiation Oncology
Volume	27
Issue number	3
DOIs	https://doi.org/10.1016/j.semradonc.2017.03.003
Publication status	Published - Jul 2017

Keywords

Journal Article
Review

Access to Document

https://doi.org/10.1016/j.semradonc.2017.03.003

Cite this

@article{9893af76ecc24fe4b949dd4eb25d9596,

title = "Stereotactic Ablative Body Radiotherapy for Lung Metastases: Where is the Evidence and What are We Doing With It?",

abstract = "This review provides an overview of the use of stereotactic ablative body radiotherapy (SABR) for pulmonary metastases. The local control rates after SABR are generally >90%. Whether this also translates into a significant improvement in overall survival is the subject of ongoing studies. New exciting opportunities including the integration of SABR with targeted and immune therapies as well as some competing treatment strategies are discussed.",

keywords = "Journal Article, Review",

author = "Shankar Siva and Slotman, {Ben J}",

year = "2017",

month = jul,

doi = "https://doi.org/10.1016/j.semradonc.2017.03.003",

language = "English",

volume = "27",

pages = "229--239",

journal = "Semininars in Radiation Oncology",

issn = "1532-9461",

publisher = "W.B. Saunders Ltd",

number = "3",

}

TY - JOUR

T1 - Stereotactic Ablative Body Radiotherapy for Lung Metastases

T2 - Where is the Evidence and What are We Doing With It?

AU - Siva, Shankar

AU - Slotman, Ben J

PY - 2017/7

Y1 - 2017/7

N2 - This review provides an overview of the use of stereotactic ablative body radiotherapy (SABR) for pulmonary metastases. The local control rates after SABR are generally >90%. Whether this also translates into a significant improvement in overall survival is the subject of ongoing studies. New exciting opportunities including the integration of SABR with targeted and immune therapies as well as some competing treatment strategies are discussed.

AB - This review provides an overview of the use of stereotactic ablative body radiotherapy (SABR) for pulmonary metastases. The local control rates after SABR are generally >90%. Whether this also translates into a significant improvement in overall survival is the subject of ongoing studies. New exciting opportunities including the integration of SABR with targeted and immune therapies as well as some competing treatment strategies are discussed.

KW - Journal Article

KW - Review

U2 - https://doi.org/10.1016/j.semradonc.2017.03.003

DO - https://doi.org/10.1016/j.semradonc.2017.03.003

M3 - Review article

C2 - 28577830

SN - 1532-9461

VL - 27

SP - 229

EP - 239

JO - Semininars in Radiation Oncology

JF - Semininars in Radiation Oncology

IS - 3

ER -